Christopher Begley - Zimmer Biomet Lead Independent Director
| ZBH Stock | USD 102.35 0.09 0.09% |
Director
Mr. Christopher B. Begley is Independent Director of the Company. Executive Chairman of the Board of Hospira, Inc. from May 2007 until his retirement in January 2012. Mr. Begley also served as Chief Executive Officer from April 30, 2004, when Hospira was spun off from Abbott Laboratories, to March 2011. Prior to that, Mr. Begley served in various positions with Abbott between 1986 and 2004, most recently as Senior Vice President of Abbotts Hospital Products division. He earned a bachelors degree from Western Illinois University and an MBA from Northern Illinois University. Christopher B. Begleys past experience as the Chairman and CEO of Hospira, Inc., a leading provider of injectable drugs and infusion technologies, and previously as the senior vice president of two Abbott divisions, has provided him with extensive management experience at two multinational, publicly traded healthcare companies. In these senior leadership roles, Mr. Begley gained indepth knowledge of the healthcare industry and strategies for developing and marketing products in this highly regulated area. He also gained significant experience in strategic planning, risk management and financial management. Mr. Begley serves, and has served for more than 10 years, as a director of other public companies, including service as chairman of the board. since 2021.
| Age | 68 |
| Tenure | 4 years |
| Professional Marks | MBA |
| Phone | 574 373 3333 |
| Web | https://www.zimmerbiomet.com |
Zimmer Biomet Management Efficiency
The company has Return on Asset of 0.0465 % which means that on every $100 spent on assets, it made $0.0465 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0725 %, implying that it generated $0.0725 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kristen CFA | Integer Holdings Corp | N/A | |
| Sally Blount | Abbott Laboratories | 59 | |
| Joel Suiter | SurModics | N/A | |
| William Link | Edwards Lifesciences Corp | 73 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| Denise OLeary | Medtronic PLC | 62 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Patricia Gonzalez | Abbott Laboratories | 49 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Allan Golston | Stryker | 54 | |
| Sherilyn McCoy | Stryker | 62 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Yoshiaki Fujimori | Boston Scientific Corp | 69 | |
| Roch Doliveux | Stryker | 64 | |
| Robert Alpern | Abbott Laboratories | 70 | |
| Donna James | Boston Scientific Corp | 63 | |
| Randall Hogan | Medtronic PLC | 64 | |
| John Workman | CONMED | 69 | |
| Giovanni Caforio | Stryker | 56 | |
| Jerome Lande | CONMED | 45 | |
Management Performance
| Return On Equity | 0.0725 | ||||
| Return On Asset | 0.0465 |
Zimmer Biomet Holdings Leadership Team
Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sreelakshmi Kolli, Independent Director | ||
| Didier Deltort, President - Europe, Middle East and Africa | ||
| Carrie Nichol, Chief Accounting Officer, Vice President Controller | ||
| Arthur Higgins, Independent Director | ||
| Kenneth Tripp, Senior Logistics | ||
| Michael Michelson, Independent Director | ||
| Larry Glasscock, Independent Non-Executive Chairman of the Board | ||
| Nitin Goyal, Chief Science, Technology and Innovation Officer | ||
| Ellison Humphrey, Senior Vice President, Chief Transformation Officer | ||
| Chad JD, General VP | ||
| Derek Davis, Chief Accounting Officer, Vice President, Controller | ||
| Ivan Tornos, Group President - Global Businesses and Americas | ||
| Angela Main, Global VP | ||
| Wilfred Zuilen, President - Europe, Middle East and Africa | ||
| Suketu Upadhyay, Chief Financial Officer, Executive Vice President | ||
| Zeeshan Tariq, Senior Officer | ||
| Christopher Begley, Lead Independent Director | ||
| Bryan Hanson, Chairman of the Board, President, Chief Executive Officer | ||
| Sang Yi, President Asia Pacific | ||
| Betsy Bernard, Independent Director | ||
| Keri Mattox, Senior Vice President - Investor Relations, Chief Communications Officer | ||
| Maria Hilado, Independent Director | ||
| Rachel Ellingson, Senior Vice President Chief Strategy Officer, Executive Officer | ||
| Kristen Cardillo, Senior Officer | ||
| Nitin MD, Technology Science | ||
| Chad Phipps, Senior Vice President, General Counsel, Secretary | ||
| Syed Jafry, Independent Director | ||
| Paul Stellato, Controller VP | ||
| Michael Farrell, Independent Director | ||
| Lori Winkler, Chief Human Resource Officer, Senior Vice President | ||
| Zachary CPA, Director Relations | ||
| David DeMartino, Senior Relations | ||
| Gail Boudreaux, Independent Director | ||
| Shaun Braun, Senior Officer | ||
| Robert Hagemann, Independent Director |
Zimmer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0725 | ||||
| Return On Asset | 0.0465 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 26.05 B | ||||
| Shares Outstanding | 199.06 M | ||||
| Shares Owned By Institutions | 93.59 % | ||||
| Number Of Shares Shorted | 6.22 M | ||||
| Price To Earning | 77.41 X | ||||
| Price To Book | 1.63 X |
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.